The Company announced its fourth quarter and full year 2017 financial results.
The Company plans on attending the Cowen Health Care Conference on Wednesday, March 14 at 10:40 a.m. ET in Boston and the Barclays Global Healthcare Conference on Thursday, March 15 in Miami.
The Company announced its first quarter 2016 financial and operational results for the quarter ended March 31, 2016.
The Company will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 10, 2016 at 5:00 p.m. PT.
The Company will host a call on Monday, April 25, 2016, at 6:00 p.m. ET to update the investment community regarding the strategic collaboration with Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY).
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced a licensing agreement for Aratana’s FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs.
The Company will host a live conference call on Friday, May 6, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ending March 31, 2016.
The Company announced plans to showcase Galliprant pivotal efficacy and safety data at the American Animal Hospital Association (AAHA) annual conference in Austin, Texas on Saturday, April 2, 2016.
Attend our Emerging Therapeutic Technologies CE sessions on osteoarthritis and post-operative pain management, inappetence and osteosarcoma at the American Animal Hospital Association Conference 2016.
At the Western Veterinary Conference 2016, Aratana sponsored 12 scientific CE sessions and interacted with thousands of veterinary professionals at their exhibit booth to introduce the emerging therapeutics they are bringing to the market.
Today the Company announced the Company submitted an administrative New Animal Drug Application (NADA) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for appetite stimulation for dogs.
Today the Company announced the Food and Drug Administration’s Center for Veterinary Medicine (CVM) approved a therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs.
Aratana Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
Attend our Emerging Therapeutic Technologies CE sessions on Tuesday, March 8 and Wednesday, March 9 to discover novel therapeutics in development for osteoarthritis, post-operative pain, inappetence, lymphoma and osteosarcoma.
The Aratana CE dinner program was an informative evening for VOS attendees. On the evening of February 29 in Big Sky, Montana, conference attendees learned about new therapeutics in development for their patients from Aratana.
The Company plans to present at the Barclays Capital Global Healthcare Conference on Wednesday, March 16 at 3:50 p.m. ET in Miami at the Loews Miami Beach Hotel.
VOS meeting attendees are invited to the Aratana CE dinner program to learn about new therapeutic solutions in development for their patients.
The Company received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for a therapeutic for appetite stimulation in dogs.